ROG CH0012032048

Report

Delayed Swiss Exchange - 07/30 11:31:05 am
350.35	CHF		+0.79%

08:09a	ROCHE : Invitation to Roche's Virtual Pharma Day - Tuesday, 14th September 2021	PU
07/29	PTC THERAPEUTICS : Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi	AQ
07/29	ROCHE : Morningstar Lowers Price Target on Roche, Maintains Buy Recommendation	MT

Company

Business Summary

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Number of employees : 101 465 people.

Sales per Business

	2019		2020		Delta
Pharmaceuticals	50 714.00	82.5%	46 491.00	79.7%	-8.33%
Diagnostics	13 037.00	21.2%	13 852.00	23.8%	+6.25%
CHF in Million

Sales per region

	2019		2020		Delta
United States	31 164.00	50.7%	28 630.00	49.1%	-8.13%
Rest of Europe	9 672.00	15.7%	9 785.00	16.8%	+1.17%
Rest of Asia	8 717.00	14.2%	8 627.00	14.8%	-1.03%
Japan	4 674.00	7.6%	4 254.00	7.3%	-8.99%
Germany	3 084.00	5%	3 352.00	5.7%	+8.69%
Latin America	2 858.00	4.6%	2 393.00	4.1%	-16.27%
Africa, Australia and Oceania	1 359.00	2.2%	1 318.00	2.3%	-3.02%
Switzerland	1 237.00	2%	1 101.00	1.9%	-10.99%
Rest of North America	986.00	1.6%	883.00	1.5%	-10.45%
CHF in Million

Managers

Name	Title	Age	Since
Severin Schwan	Chief Executive Officer & Executive Director	53	2015
Alan Hippe	Chief Financial & Information Technology Officer	69	2011
Urs Jaisli	Chief Compliance Officer	64	2015
André S. Hoffmann	Vice Chairman	62	2012
Christoph Franz	Chairman	61	2014
Karl Mahler, Dr.	Head-Investor Relations	-	2010
Gottlieb A. Keller, Dr.	Secretary & General Counsel	66	-
Michael D. Varney, Dr.	Head-Genentech Research & Early Development	61	2015
William Pao, Dr.	Head-Pharma Research & Early Development	53	2018
Per-Olof Attinger	Secretary-Executive Committee & Head-CEO Office	60	2010

Members of the board

Name	Title	Age	Since
Christoph Franz	Chairman	61	2014
Paul Bulcke	Non-Executive Director	65	2012
André S. Hoffmann	Vice Chairman	62	2012
Severin Schwan	Chief Executive Officer & Executive Director	53	2015
Bernard J. Poussot	Non-Executive Director	68	2015
Richard P. Lifton, Dr.	Non-Executive Director	67	2015
Claudia Süssmuth Dyckerhoff, Dr.	Director	53	2016
Julie Brown	Director	58	2016
Anita Hauser	Director	51	2017
Hans Clevers, Dr.	Director	62	2019

Equities

	Vote	Quantity	Free-Float		Company-owned shares		Total Float
Stock A	1	702,562,700	693,122,360	98.7%	8,301,797	1.2%	83.4%
Stock B	1	160,000,000	26,334,672	16.5%	0	0.0%	83.4%

Shareholders

Name	Equities	%
Norges Bank Investment Management	19,938,101	2.84%
The Vanguard Group, Inc.	18,590,608	2.65%
Fidelity Management & Research Co. LLC	12,255,352	1.74%
UBS Asset Management Switzerland AG	11,152,736	1.59%
BlackRock Fund Advisors	11,114,595	1.58%
Roche Holding AG	9,436,750	1.34%
Credit Suisse Asset Management (Schweiz) AG	8,732,718	1.24%
Massachusetts Financial Services Co.	7,595,787	1.08%
Zürcher Kantonalbank (Investment Management)	6,727,921	0.96%
Flossbach von Storch AG	6,549,450	0.93%

Name	Equities	%
Dodge & Cox	30,436,399	0.54%
Loomis, Sayles & Co. LP	16,159,861	0.29%
Principal Global Investors LLC	10,018,857	0.18%
ARK Investment Management LLC	4,991,355	0.089%
AllianceBernstein LP	3,903,573	0.069%
Amundi Asset Management US, Inc.	3,778,895	0.067%
Mairs & Power, Inc.	3,577,000	0.064%
Capital Research & Management Co. (World Investors)	2,809,317	0.050%
Capital Research & Management Co. (Global Investors)	1,850,168	0.033%
Fayez Sarofim & Co.	1,213,140	0.022%

Name	Equities	%
Hoffmann Family	72,018,000	45.0%
Novartis AG	53,332,863	33.3%
Maja Oeri	8,091,900	5.06%
APG Asset Management NV	1,916,612	1.20%
Canada Pension Plan Investment Board	1,242,618	0.78%
Artisan Partners LP	1,022,567	0.64%
Schroder Investment Management Ltd.	822,824	0.51%
The Vanguard Group, Inc.	795,647	0.50%
RBC Global Asset Management (UK) Ltd.	768,437	0.48%
J.O. Hambro Capital Management Ltd.	743,124	0.46%

Holdings

Name	Equities	%	Valuation
CHUGAI PHARMACEUTICAL CO., LTD. (4519)	1,005,670,000	59.9%	39,886,109,174 USD
ROCHE HOLDING AG (ROG)	9,436,750	1.34%	3,558,369,773 USD
SENSEONICS HOLDINGS, INC. (SENS)	35,046,418	8.19%	134,578,245 USD
ALIGOS THERAPEUTICS, INC. (ALGS)	3,092,340	8.10%	63,037,351 USD
VAXCYTE, INC. (PCVX)	2,587,754	5.04%	58,250,343 USD
ELOXX PHARMACEUTICALS, INC. (ELOX)	2,532,270	2.94%	5,039,217 USD
TEMPEST THERAPEUTICS INC. (TPST)	72,612	1.09%	811,802 USD

Company contact information

Roche Holding AG
Grenzacherstrasse 124
Basel, Basel-Stadt (Basle Town) 4070

Phone : +41.61.688.11.11
Fax : +41.61.691.93.91
Web : http://www.roche.com